Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance. These strategies include heightening T-cell response...
Main Authors: | Anusha Thadi, Marian Khalili, William F. Morano, Scott D. Richard, Steven C. Katz, Wilbur B. Bowne |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/6/3/54 |
Similar Items
-
Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes
by: Mefotse Saha Cyrelle Ornella, et al.
Published: (2023-04-01) -
Establishment of a Mouse Ovarian Cancer and Peritoneal Metastasis Model to Study Intraperitoneal Chemotherapy
by: Günther A. Rezniczek, et al.
Published: (2020-12-01) -
Effects of Hyperthermia and Hyperthermic Intraperitoneal Chemoperfusion on the Peritoneal and Tumor Immune Contexture
by: Daryl K. A. Chia, et al.
Published: (2023-08-01) -
Intraperitoneal metastasis of ovarian cancer: new insights on resident macrophages in the peritoneal cavity
by: Taito Miyamoto, et al.
Published: (2023-04-01) -
Erratum: Thadi A.; et al. Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. <i>Vaccines</i> 2018, <i>6</i>, 54
by: Anusha Thadi, et al.
Published: (2019-01-01)